deuruxolitinib alopecia
Selected indexed studies
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1). (J Am Acad Dermatol, 2024) [PMID:39053611]
- Deuruxolitinib for Alopecia Areata. (Skin Therapy Lett, 2026) [PMID:41557935]
- Janus kinase inhibitors for alopecia areata. (J Am Acad Dermatol, 2023) [PMID:37591562]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Janus kinase inhibitors for alopecia areata. (2023) pubmed
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1). (2024) pubmed
- Deuruxolitinib for Alopecia Areata. (2026) pubmed
- Deuruxolitinib. (2012) pubmed
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis. (2024) pubmed
- Deuruxolitinib (Leqselvi) for severe alopecia areata. (2025) pubmed
- Janus kinase inhibitors for alopecia areata: a review of clinical data. (2025) pubmed
- Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update. (2025) pubmed
- The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta-Analysis Study. (2025) pubmed
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients. (2025) pubmed